Clinical Trial

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Study acronym: SOLTI-2104
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or without triptorelin.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-04; most recent amendment 2026-04-21.
Status change: Active, Not Recruiting → Recruiting 2026-04-21
Status change: Recruiting → Active, Not Recruiting 2025-05-19
Status change: Not Yet Recruiting → Recruiting 2024-02-09
Trial Details
NCT Number NCT05982093
Lead Sponsor SOLTI Breast Cancer Research Group
Conditions Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer
Enrollment 96 participants
Start Date 2023-02-03
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-24